RA Capital Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

RA Capital Management’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,163,271	Closed	-$109M	–	90
2020 Q3	$109M	Buy	2,163,271 +600	+0%	+$27K	2%	14
2020 Q2	$103M	Hold	2,162,671	–	–	2.01%	18
2020 Q1	$106M	Hold	2,162,671	–	–	3.35%	7
2019 Q4	$124M	Hold	2,162,671	–	–	3.76%	7
2019 Q3	$77.8M	Hold	2,162,671	–	–	4.63%	6
2019 Q2	$113M	Hold	2,162,671	–	–	6.05%	6
2019 Q1	$91.1M	Hold	2,162,671	–	–	3.93%	8
2018 Q4	$59.2M	Hold	2,162,671	–	–	3.45%	10
2018 Q3	$21.6M	Hold	2,162,671	–	–	1.15%	19
2018 Q2	$44M	Buy	+2,162,671	New	+$45.3M	2.86%	14

Other funds holding EIDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

RA Capital Management's EIDX Position: Q4 2020 in Review

RA Capital Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q4 2020, closing a stake of 2,163,271 shares — an estimated $109M sold.

RA Capital Management first reported a position in EIDX in Q2 2018 and held it in 10 quarters. The position peaked at $124M in Q4 2019. 121 funds tracked by Wall St. Rank hold EIDX as of Q4 2020.

RA Capital Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
RA Capital Management sold 2,163,271 Eidos Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $109M.
RA Capital Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 10 quarters.
RA Capital Management's Eidos Therapeutics, Inc. Common Stock position peaked at $124M in Q4 2019.
121 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q4 2020.

Based on RA Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.